- 11:24 PM Student visa applications to US, UK see 25% drop
- 10:46 PM Astec LifeSciences to start a project in Q3FY11
- 10:20 PM Rangebound session for Nifty ahead of Nov series e...
- 09:30 PM Politics stirs over Ayodhya mosque report
- 09:23 PM Clean energy, better homes cut pollution, save liv...
- 09:11 PM US to face stimulus aftershocks: Warren Buffett
- 09:02 PM Expert stock/sector picks for tricky markets
- 08:53 PM Indian techie logging out of downturn gloom
- 08:52 PM Expert stock/sector picks in these markets
- 08:44 PM Govt not to relook at arrested CLB member's probe
Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Didanosine Delayed Release (Enteric-Coated) Capsules 125mg, 200mg, 250mg and 400mg
Didanosine Delayed Release Capsules is the generic version of Bristol Myer Squibb's Videx® EC (Didanosine) Delayed-release Capsules, 125mg, 200mg, 250mg and 400mg and is indicated for the treatment of HIV-1 infections in adults.
This is Aurobindo’s 78th ANDA approval from the USFDA
Sourced From: Aurobindo Pharma Limited
|
|
Business
Business News | Economy | Earnings | BSE NSE Notices
General News
Current Affairs | Politics | World News | Sports | Entertainment
Corporate Strategy
Management | Advertising | Marketing | Legal
Personal Finance
Tax | Insurance | Credit Cards | Loans | Property | Retirement | Investment Help | Financial Planning | Fixed Income
Markets
Local Market | Global Market | Market Cues | Analysis | Expert & FII outlook | Brokerage Recomendation
Stocks
Stocks in News | Expert Advice | ADRs & GDRs | IPO
Mutual Funds
News | Advice | MF Analysis | Fund Managers Views
Lifestyle
Travel | Wellness | Technology | Auto| Books
-
Most Read
-
Most Viewed
- 10 Companies that FIIs love
- 10 companies that MF managers love
- Ex-bonus, RIL will see correction: SP Tulsian
- Mkts to remain strong; bet on midcaps: Ramesh Damani
- Sudarshan Sukhani's top five picks for today's trade
- Nifty to test 5500 post 5-7% correction: JM Financial
- Ganeshaspeaks: Market prediction for Nov 25
- Expert sector picks to power your portfolio ahead
- Below Rs 94, Mahindra Satyam can test Rs 85: Bhambwani
- Mah Satyam looks at out-of-court settlement with creditors
- S&P raises fears over health of some banks
Source: ft.com
- Auto sector growth to push up demand for rubber
Source: Business Line
- High networth individuals see glitter in commodities
Source: Business Line
- Tatas may launch electric Indica by early 2011
Source: Business Line
